Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1997-1-29
pubmed:abstractText
We have discovered a remarkable synergistic antimalarial interaction between rufigallol and the structurally similar compound exifone. The synergistic effects were produced in chloroquine-susceptible and chloroquine-resistant clones of Plasmodium falciparum. The degree of potentiation as estimated by standard isobolar analysis was approximately 60-fold for experiments initiated with asynchronous parasites. The most pronounced synergism was observed in experiments with synchronized trophozoite-infected erythrocytes, in which the degree of synergy was at least 300-fold. While the mechanism underlying this drug potentiation remains unresolved, it is hypothesized that rufigallol acts in pro-oxidant fashion to produce oxygen radicals inside parasitized erythrocytes. These radicals would attack exifone, thereby initiating its transformation into a more potent compound, a xanthone.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-15463474, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-1590699, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-2164790, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-2648881, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-2737388, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-2737398, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-2901124, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-3013969, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-3284758, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-3290484, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-3544220, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-3628440, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-383936, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-563439, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-781840, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-7838186, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-8183310, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-8225025, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-8264727, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-8593000, http://linkedlifedata.com/resource/pubmed/commentcorrection/8726010-8604177
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
40
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1408-11
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1996
pubmed:articleTitle
Potentiation of the antimalarial agent rufigallol.
pubmed:affiliation
Medical Research Service, Department of Veterans Affairs Medical Center, Portland, Oregon 97201, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S., Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't